Serotonin and GI Disorders: An Update on Clinical and Experimental Studies | Zendy

Marcus M. Manocha | Zendy; Waliul I. Khan | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Serotonin and GI Disorders: An Update on Clinical and Experimental Studies

Author(s) -

Marcus M. Manocha,

Waliul I. Khan

Publication year - 2012

Publication title -

clinical and translational gastroenterology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.673

H-Index - 35

ISSN - 2155-384X

DOI - 10.1038/ctg.2012.8

Subject(s) - enterochromaffin cell , irritable bowel syndrome , medicine , immune system , bioinformatics , functional gastrointestinal disorder , inflammation , serotonin , inflammatory bowel diseases , microscopic colitis , inflammatory bowel disease , immune dysregulation , disease , immunology , biology , receptor

The gastrointestinal (GI) tract is the largest producer of serotonin (5-hydroxytryptamine (5-HT)) in the body, and as such it is intimately connected with GI function and physiology. 5-HT produced by enterochromaffin (EC) cells is an important enteric mucosal signaling molecule and has been implicated in a number of GI diseases, including inflammatory bowel disease and functional disorders such as irritable bowel syndrome. This review will focus on what is known of basic 5-HT physiology and also on the emerging evidence for its novel role in activation of immune response and inflammation in the gut. Utilizing pubmed.gov, search terms such as "5-HT," "EC cell," and "colitis," as well as pertinent reviews, were used to develop a brief overview of EC cell biology and the association between 5-HT and various GI disorders. It is the aim of this review to provide the readers with an update on EC cell biology and current understanding on the role of 5-HT in GI disorders specifically in inflammatory conditions.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research